Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|
| Operating activities: | ||
| Net loss | $$(207,174) | (23,387) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 6,734 | 4,494 |
| Amortization of right-of-use operating lease assets | 6,990 | 5,177 |
| Amortization of other assets | 1,361 | 1,180 |
| Amortization of discount on investments, net | (9,533) | (12,978) |
| Amortization of debt issuance costs | 4,150 | 3,288 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's D&A?
- Ionis Pharmaceuticals (IONS) reported D&A of $3.43M in Q2 2026.
- How has Ionis Pharmaceuticals's D&A changed year-over-year?
- Ionis Pharmaceuticals's D&A increased by 51.5% year-over-year, from $2.27M to $3.43M.
- What is the long-term trend for Ionis Pharmaceuticals's D&A?
- Over 4 years (2021 to 2025), Ionis Pharmaceuticals's D&A has grown at a -10.3% compound annual growth rate (CAGR), from $15.49M to $10.01M.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Ionis Pharmaceuticals's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude